Adjuvant therapy for hepatocellular carcinoma after curative treatment

Digestive Diseases

Volumn 32, Issue 6, 2014, Pages 747-754

  Jeng, Wen Juei ^a   Lin, Chen Chun ^a   Chen, Wei Ting ^a   Sheen, I Shyan ^a   Lin, Chun Yen ^a   Lin, Shi Ming ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Antiviral treatment; Cirrhosis; Interferon; Micrometastases; Recurrence prevention; Transcatheter arterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BRANCHED CHAIN AMINO ACID; FARNOQUINONE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; RETINOID; RIBAVIRIN; SORAFENIB; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONFERENCE PAPER; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROMETASTASIS; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; FEMALE; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84910672501     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000368017     Document Type: Conference Paper

References (112)

1. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-245.
2. Chang MH: Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res 2014;193:75-95.
3. Singh S, Singh PP, Roberts LR, Sanchez W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014;11:45-54.
4. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al: Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63-70.
5. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, et al: Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011;98:552-557.
6. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207.
7. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al: Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890-897.
8. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-507.
9. Guerrieri F, Belloni L, Pediconi N, Levrero M: Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis 2013;33:147-156.
10. Lok AS: Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127 (5 suppl 1):S303-S309.
11. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
12. Qu LS, Jin F, Huang XW, Shen XZ: High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg 2010;14:1111-1120.
13. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al: Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-1914.
14. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
15. Sohn W, Paik YH, Kim JM, Kwon CH, Joh JW, Cho JY, et al: HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol 2014;21:2429-2435.
16. Ank N, West H, Paludan SR: IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006;26:373-379.
17. Jonasch E, Haluska FG: Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55.
18. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
19. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169.e4-2179.e4.
20. Abu-Amara M, Feld JJ: Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? Semin Liver Dis 2013;33:157-166.
21. Lai CL, Yuen MF: Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013;57:399-408.
22. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009;16:265-271.
23. Miyake Y, Kobashi H, Yamamoto K: Metaanalysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009;44:470-475.
24. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL: Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-1077.
25. Qu LS, Jin F, Huang XW, Shen XZ: Interferon-alpha therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol 2010;102:796-801.
26. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-842.
27. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-465.
28. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al: Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012;255:8-17.
29. Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, et al: Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol 2013;31:766-773.
30. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al: Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-657.
31. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al: A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013;57:230-236.
32. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, et al: Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013;58:495-501.
33. Shimomura S, Ikeda N, Saito M, Ishii A, Takashima T, Sakai Y, et al: Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 2010;5:559-566.
34. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K: Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010;17:287-292.
35. Miyake Y, Iwasaki Y, Yamamoto K: Metaanalysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer 2010;127:989-996.
36. Singal AK, Freeman DH Jr, Anand BS: Metaanalysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;32:851-858.
37. Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, et al: Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol 2012;19:418-425.
38. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232.
39. Kudo Y, Terao H, Arita T, Kawasaki H, Sato S, Abe H, et al: Interferon therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after treatment of recurrent hepatocellular carcinoma: a successful case. Intern Med 2002;41:202-206.
40. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306.
41. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-382.
42. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554.
43. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al: Effects of longterm postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963-967.
44. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN: Antiviral therapy after nonsurgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:1553-1559.
45. Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T: Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer 2013;2:40-46.
46. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
47. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al: Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
48. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1:41-50.
49. Verslype C, Rosmorduc O, Rougier P, Group E G W: Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl 7): vii41-vii48.
50. European Association for Study of Liver, European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012;48:599-641.
51. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, et al: Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011;81(suppl 1):158-164.
52. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-1118.
53. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
54. Kim JH, Yim HJ, Lee KG, Kim SY, Jung ES, Jung YK, et al: Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study. Hepatol Int 2011, Epub ahead of print.
55. Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al: Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs.radiofrequency ablation alone. Eur J Radiol 2012;81:e189-e193.
56. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013;31:426-432.
57. Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, et al: Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol 2014, Epub ahead of print.
58. Kudo M: Signaling pathway and moleculartargeted therapy for hepatocellular carcinoma. Dig Dis 2011;29:289-302.
59. Zhu AX: Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008;112:250-259.
60. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, et al: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 2011;10:169-177.
61. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70.
62. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
63. Fukuda H, Numata K, Moriya S, Shimoyama Y, Ishii T, Nozaki A, et al: Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation-propensity score matching analysis. Radiology 2014;272:598-604.
64. Wang SN, Chuang SC, Lee KT: Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res 2014;44:523-531.
65. Printz C: Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009;115:4646.
66. Shindoh J, Kaseb A, Vauthey JN: Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer 2013;2:47-54.
67. Yamamoto M, Arii S, Sugahara K, Tobe T: Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996;83:336-340.
68. Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, et al: Uraciltegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006;44:891-895.
69. Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, et al: Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 2010;17:3137-3144.
70. Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, et al: Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 2012;38:286-295.
71. Furie B, Bouchard BA, Furie BC: Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999;93:1798-1808.
72. Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T: Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 1999;69:24-26.
73. Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata H: Changes of plasma des-gammacarboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer 1992;69:31-38.
74. Yamamoto T, Nakamura H, Liu W, Cao K, Yoshikawa S, Enomoto H, et al: Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K (2). J Gastroenterol 2009;44:228-235.
75. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, et al: The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006;106:867-872.
76. Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, et al: Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007;22:518-522.
77. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, et al: Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009;51:315-321.
78. Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al: Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011;54:532-540.
79. Ishizuka M, Kubota K, Shimoda M, Kita J, Kato M, Park KH, et al: Effect of menatetrenone, a vitamin K2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res 2012;32:5415-5420.
80. Zhong JH, Mo XS, Xiang BD, Yuan WP, Jiang JF, Xie GS, et al: Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS One 2013;8:e58082.
81. Riaz IB, Riaz H, Riaz T, Rahman S, Amir M, Badshah MB, et al: Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2012;12:170.
82. Chu KJ, Lai EC, Yao XP, Zhang HW, Lau WY, Fu XH, et al: Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation - a systematic review and meta-analysis. Asian J Surg 2010;33:120-126.
83. De Visser KE, Coussens LM: The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006;13:118-137.
84. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, et al: Treatment of nonresectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-896.
85. Miamen AG, Dong H, Roberts LR: Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer 2012;1:226-237.
86. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-1841.
87. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-149.
88. Xie F, Zhang X, Li H, Zheng T, Xu F, Shen R, et al: Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One 2012;7:e42879.
89. Zhong JH, Ma L, Wu LC, Zhao W, Yuan WP, Wu FX, et al: Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract 2012;66:21-27.
90. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76.
91. Ando N, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Tanaka T, et al: Expression of retinoid X receptor alpha is decreased in 3 '-methyl-4-dimethylaminoazobenzene-induced hepatocellular carcinoma in rats. Oncol Rep 2007;18:879-884.
92. Shimizu M, Imai K, Takai K, Moriwaki H: Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects. Curr Cancer Drug Targets 2012;12:1119-1128.
93. Shimizu M, Sakai H, Moriwaki H: Chemoprevention of hepatocellular carcinoma by acyclic retinoid. Front Biosci 2011;16:759-769.
94. Shimizu M, Shirakami Y, Imai K, Takai K, Moriwaki H: Acyclic retinoid in chemoprevention of hepatocellular carcinoma: targeting phosphorylated retinoid X receptor-a for prevention of liver carcinogenesis. J Carcinog 2012;11:11.
95. Shimizu M, Takai K, Moriwaki H: Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 2009;100:369-374.
96. Kajiwara K, Okuno M, Kobayashi T, Honma N, Maki T, Kato M, et al: Oral supplementation with branched-chain amino acids improves survival rate of rats with carbon tetrachloride-induced liver cirrhosis. Dig Dis Sci 1998;43:1572-1579.
97. Yoshida T, Muto Y, Moriwaki H, Yamato M: Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn 1989;24:692-698.
98. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al: Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a doubleblind, randomized trial. Gastroenterology 2003;124:1792-1801.
99. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al: Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990;11:92-101.
100. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg 1997;84:1525-1531.
101. Meng WC, Leung KL, Ho RL, Leung TW, Lau WY: Prospective randomized control study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust NZ J Surg 1999;69:811-815.
102. Okabayashi T, Iyoki M, Sugimoto T, Kobayashi M, Hanazaki K: Oral supplementation with carbohydrate- and branchedchain amino acid-enriched nutrients improves postoperative quality of life in patients undergoing hepatic resection. Amino Acids 2011;40:1213-1220.
103. Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, et al: Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011;26:1547-1553.
104. Nishikawa H, Osaki Y, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, et al: The effect of longterm supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013;47:359-366.
105. Ichikawa K, Okabayashi T, Maeda H, Namikawa T, Iiyama T, Sugimoto T, et al: Oral supplementation of branched-chain amino acids reduces early recurrence after hepatic resection in patients with hepatocellular carcinoma: a prospective study. Surg Today 2013;43:720-726.
106. Kuroda H, Ushio A, Miyamoto Y, Sawara K, Oikawa K, Kasai K, et al: Effects of branchedchain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010;25:1550-1555.
107. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z: Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006;13:2101-2111.
108. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, et al: Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009;50:958-968.
109. Kaibori M, Ishizaki M, Matsui K, Kwon AH: Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010;102:462-468.
110. Funaki NO, Tanaka J, Seto SI, Kasamatsu T, Kaido T, Imamura M: Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 1997;25:564-568.
111. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893.
112. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.